论文部分内容阅读
目的对VDR基因Bsm1、Fok1位点多态性与晚期肺腺癌的化疗敏感性的关系进行探讨。方法采用PCR-RFLP方法检测52例接受铂类药物化疗的晚期肺腺癌患者的维生素D受体(VDR)基因多态性,比较不同基因型对化疗敏感性的影响。结果 52例患者接受并完成GP/GC方案化疗2个周期,其中17例PR,24例SD,10例PD,1例CR。总体化疗有效率(CR+PR)为34.6%;疾病控制率(CR+PR+SD)为80.8%。化疗有效组Bsm1位点Bb、bb基因型分布频率分别为91.3%、8.7%,无效组分别为94.7%、5.3%。2组基因型频率分布差异无统计学意义(P>0.05)。化疗有效组Fok1位点FF、Ff、ff基因型分布频率分别为43.0%、52.0%、5%,无效组分别为41.9%、50.0%,8.1%。2组基因型频率分布差异无统计学意义(P>0.05)。结论 VDR基因Bsm1、Fok1位点多态性与GP/GC方案化疗敏感性之间无相关。
Objective To investigate the relationship between VDR gene Bsm1 and Fok1 polymorphisms and the chemosensitivity of advanced lung adenocarcinoma. Methods VDR genotypes were determined by PCR-RFLP in 52 patients with advanced lung adenocarcinoma receiving platinum-based chemotherapy. The effects of different genotypes on chemosensitivity were compared. Results Fifty-two patients underwent two cycles of GP / GC chemotherapy, of which 17 were PR, 24 were SD, 10 were PD, and 1 was CR. The overall response rate (CR + PR) was 34.6%. The disease control rate (CR + PR + SD) was 80.8%. The frequencies of Bb and bb genotypes in Bsm1-treated group were 91.3% and 8.7% respectively, while those in ineffective group were 94.7% and 5.3% respectively. There was no significant difference in genotype frequency distribution between the two groups (P> 0.05). The frequencies of FF, Ff and ff genotypes in Fok1 group were 43.0%, 52.0% and 5% respectively, while those in ineffective group were 41.9%, 50.0% and 8.1% respectively. There was no significant difference in genotype frequency distribution between the two groups (P> 0.05). Conclusion There is no correlation between VDR gene Bsm1 and Fok1 polymorphisms and the chemosensitivity of GP / GC regimen.